Related Experiment Video
Updated: Oct 21, 2025
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
9.9K
Advances in myelodysplastic syndrome
1MDS Unit, Department of Experimental and Clinical Medicine, Hematology, AOU Careggi, University of Florence , Florence , Italy.
Current Opinion in Oncology
|September 2, 2021
Summary
Recent advancements in myelodysplastic syndromes (MDS) diagnosis and therapy offer personalized treatment strategies. Novel agents and improved prognostic tools enhance clinical management and patient outcomes.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Accurate diagnosis and prognostication are crucial for effective clinical management.
Purpose of the Study:
- To review recent improvements in the diagnosis, prognostication, and therapy of MDS.
- To discuss the relevance of these advancements for clinical management.
Main Methods:
- Review of recent analytical methods for cytogenetic and molecular assessment.
- Evaluation of novel therapeutic agents and treatment strategies.
Main Results:
- Improved prognostic stratification through integration of clinical and genomic data.
- Promising clinical results with novel agents (e.g., luspatercept, imetelstat, pevonedistat, magrolimab, venetoclax, sabatolimab, enasidenib, ivosidenib) in various MDS settings.
- Luspatercept approval for transfusion-dependent, ESA-resistant/relapsed LR-MDS, achieving transfusion independence in nearly 50% of patients.
Conclusions:
- Enhanced diagnosis and prognostic stratification enable more precise and personalized MDS treatment.
- Novel agent combinations and improved therapeutic algorithms are expected to enhance patient outcomes.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
582
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
582
01:15Differentiation of Common Myeloid Progenitor Cells
3.5K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.5K
01:22iPS Cell Differentiation
2.9K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.9K